The clinical impact of patients with bloodstream infection with different groups of Viridans group streptococci by using matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS)

Ting-Yi Su, MD\textsuperscript{a}, Ming-Hsun Lee, MD, PhD\textsuperscript{a}, Ching-Tai Huang, MD, PhD\textsuperscript{a}, Tsui-Ping Liu, BS\textsuperscript{b,c}, Jang-Jih Lu, MD, PhD\textsuperscript{b,c,∗}

Abstract
The accuracy of matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) for identifying viridans group streptococci (VGS) was improving. However, the clinical impact of identifying VGS had not been well recognized. Our study had comprehensively studied the clinical manifestations and outcome of VGS blood stream infection by using MALDI-TOF MS for identification.

This retrospective study enrolled 312 adult patients with a monomicrobial blood culture positive for VGS. Blood culture was examined through MALDI-TOF MS.

The most common VGS species were the Streptococcus anginosus group (38.8%) and Streptococcus mitis group (22.8%). Most species showed resistance to erythromycin (35.6%), followed by clindamycin (25.3%) and penicillin (12.5%). Skin and soft tissue infection and biliary tract infection were significantly related to S. anginosus group bacteremia ($P = .001$ and $P = .005$, respectively). $S. \text{mitis}$ group bacteremia was related to infective endocarditis and bacteremia with febrile neutropenia ($P = .005$ and $P < .001$, respectively). Infective endocarditis was also more likely associated with $S. \text{sanguinis}$ group bacteremia ($P = .009$). $S. \text{anginosus}$ group had less resistance rate to ampicillin, erythromycin, clindamycin, and ceftriaxone ($P < .019$, $< .001$, .001, and .046, respectively). A more staying in intensive care unit, underlying solid organ malignancy, and a shorter treatment duration were independent risk factors for 30-day mortality. This study comprehensively evaluated different VGS group and their clinical manifestations, infection sources, concomitant diseases, treatments, and outcomes. Categorizing VGS into different groups by MALDI-TOF MS could help clinical physicians well understand their clinical presentations.

Abbreviations: MALDI-TOF MS = matrix-assisted laser desorption ionization–time of flight mass spectrometry, VGS = Viridans group streptococcus.

Keywords: blood stream infection, clinical impact, MALDI-TOF MS, Viridans group streptococci groups

1. Introduction
Viridans group streptococci (VGS) include different species of organisms that can be both commensal flora and pathogens in humans.\textsuperscript{[1]} VGS are considered normal flora of the oropharyngeal, urogenital, and gastrointestinal microbiota.\textsuperscript{[2]} Identification of VGS to the species level can be difficult, and previous phenotypic identification was not always accurate with controversial taxonomy, diverse clinical manifestations, and poorly classified diseases. In 1997, only 15 different streptococcal species were included in VGS.\textsuperscript{[3]} With the development of techniques such as matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS),\textsuperscript{[4–6]} and 16S rRNA, sod A gene, or gyrB gene sequencing,\textsuperscript{[6–9]} the accuracy of the identification of VGS to the species level has increased significantly. The accuracy of MALDI-TOF MS for identifying VGS to the group level was generally reliable.\textsuperscript{[6,9]} Currently, VGS are classified into 6 major groups: Streptococcus mutans, Streptococcus salivarius, Streptococcus anginosus, Streptococcus mitis, Streptococcus sanguinis, and Streptococcus bovis groups.\textsuperscript{[10]}

VGS have been reported to have relationships with some specific diseases in children, including a significant relationship with infective endocarditis\textsuperscript{[11–13]} and bacteremia in pediatric patients with cancer, particularly in febrile and neutropenic...
Some species, such as *S. mitis* or *S. sanguinis*, have been reported to be more likely to cause infective endocarditis, and several studies have demonstrated a relationship between *S. mitis* and bacteremia in patients with febrile neutropenia. However, the clinical significance of different VGS group has not been comprehensively studied, especially in adult patients. Thus, to gain an insight into the association of different VGS group with their clinical presentations, diseases, risk factors, and outcomes, we performed a comprehensive review of VGS bloodstream infections in adult patients in a tertiary care medical center between 2014 and 2015.

2. Methods

2.1. Setting

This retrospective study was conducted at Chang Gung Memorial Hospital (CGMH), Linkou, Northern Taiwan, which is a 3715-bed university-affiliated tertiary-care medical center with 308 intensive care unit (ICU) beds. All clinical specimens were processed using computer-assisted microbiology laboratory databases at a central microbiology laboratory. This study was approved by the Institutional Review Board of CGMH (201600969B0).

2.2. Study design and patients

This retrospective study reviewed 482 patients admitted to CGMH from January 2014 to December 2015 with a monomicrobial blood culture positive for VGS. Additional inclusion criteria were as follows: being aged ≥18 years, a clinical syndrome suggestive of systemic infection, with clear medical records, and being unduplicated cases. Finally, 312 (64.7%) patients were enrolled (Fig. 1). The patients with VGS bacteremia without a clinical syndrome suggestive of systemic infection were suspected contamination and excluded.

2.3. Microbiology

Blood cultures were processed in the clinical microbiology laboratory by using an automated blood culture system (BACTEC 9240 system; Becton Dickinson Diagnostic Instrument Systems, Sparks, MD). Positive blood culture was identified using the MALDI-TOF MS instrument (Bruker Daltonics, Bremen, Germany). Measurements were performed with the Bruker Biotyper MALDI-TOF MS system using FlexControl version 3.4 software with Compass Flex Series version 1.4 software and a 60-Hz nitrogen laser (337 nm wave length). Spectra ranging from 2000 to 20,000 m/z were analyzed using the MALDI Biotyper system’s automation control and the current Bruker Biotyper V.3.1 software and library [database (DB)5989 with 5989 entries]. The identification criteria used in our analysis, as outlined by the manufacturer, were as follows: A score of ≥2 indicated identification to the species level, a score between 1.7 and 1.9 indicated identification to the genus level, and a score of ≤1.7 was interpreted as unreliable identification. VGS were classified into 6 main groups: *S. anginosus* group, comprising *S. anginosus*, *S. constellatus*, and *S. intermedius*; *S. mitis* group, comprising *S. mitis*, *S. oralis*, and *S. infantis*; *S. bovis* group, comprising *S. gallolyticus* and *S. lutei*; *S. sanguinis* group, comprising *S. sanguinis*, *S. parasangunis*, and *S. gordoni*; *S. salivarius* group, comprising *S. salivarius*; and *S. mutans* group, comprising *S. mutans*. Although *S. pneumoniae* and *S. pseudomonae* also belonged to *S. mitis* group by the DNA association, we excluded them due to the fact that their clinical manifestations are different from the other VGS. *S. pneumoniae* and *S. pseudomonae* were excluded by the results of MALDI-TOF MS and Optochin test. As the previous study did not completely show reliable results of *S. mitis* group identification by MALDI-TOF Biotyper system, we also arranged 16S rRNA sequencing by randomized selected *S. mitis* group. The 16S rRNA gene was amplified for all the isolates using the universal primers with 8FPL (5'-AGTTTGATCCTGGCTCAG-3') and 1492R (5'-TACGGYTACCTTGTTACGACTT-3'). Species identification was performed by comparing the obtained sequences against those in the Basic Local Alignment Search Tool of GenBank database (http://www.ncbi.nlm.nih.gov/BLAST/). A sequence similarity of 99% was applied as species identification “cut-off” value for the 16S rRNA gene region.

![Flow chart of the exclusion of patients with viridans group streptococcus bacteremia.](image)
Antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute interpretive criteria for the disk diffusion method.\textsuperscript{21} Antibiotic disks (BD Microbiology Systems, Cockeysville, MD) for VGS included ampicillin, clindamycin, ceftriaxone, erythromycin, penicillin, vancomycin, and teicoplanin.

2.4. Data collection and definition

Demographic data, such as age, sex, concomitant diseases, and clinical characteristics, of patients with VGS bacteremia were retrieved by reviewing inpatient medical records. Concomitant diseases included severe renal impairment (defined as chronic kidney disease stages 4 and 5 and requiring renal replacement therapy), diabetes mellitus, cerebrovascular accident, liver cirrhosis, chronic pulmonary disease, and malignancy. Central venous catheter (CVC) placement, ventilator use, ICU stay, immunosuppressant use, and the time interval between hospitalization and occurrence of VGS bacteremia were recorded. Disease severity scores were calculated using the Pittsburgh bacteremia score on the day of VGS bacteremia occurrence.\textsuperscript{22} Pittsburgh bacteremia score was calculated as follows: ear temperature: 2 points for a temperature of \(\leq 35.5^\circ\text{C}\) or \(\geq 40.5^\circ\text{C}\); 1 point for a temperature of \(35.5^\circ\text{C} \) to \(36.0^\circ\text{C}\) or \(39.0^\circ\text{C}\) to \(39.9^\circ\text{C}\), and 0 point for a temperature of \(36.1^\circ\text{C}\) to \(38.9^\circ\text{C}\); hypotension: 2 points for an acute hypotensive event with decreases in systolic and diastolic blood pressure of \(>30\) and \(>20\) mm Hg, respectively, use of intravenous vasopressor agents, or systolic blood pressure < 90 mm Hg; receipt of mechanical ventilation: 2 points; cardiac arrest: 4 points; and mental status: alert, 0 point; disoriented, 1 point; stupor, 2 points; and comatose, 4 points. Severe sepsis was defined as sepsis plus evidence of organ dysfunction, including one of the following criteria: arterial hypoxemia [arterial oxygen tension (PaO\textsubscript{2})/fraction of inspiration O\textsubscript{2}; FiO\textsubscript{2} < 0.30]; acute oliguria (urine output < 0.5 mL/kg per hour for at least 2 h despite adequate fluid resuscitation); increase in creatinine > 0.5 mg/dL; coagulation abnormalities [international normalized ratio (INR) > 1.5, partial thromboplastin time (aPTT) > 60 seconds, and platelets < 100,000/µL]; hepatic dysfunction (elevated bilirubin); paralytic ileus; and increased capillary refill or skin mottling. Septic shock was defined as sepsis with hypotension refractory to fluid resuscitation. Neutropenia was defined as an absolute neutrophil count of \(<0.5 \times 10^9/\text{L}\).

Bacteremia sources determined from medical records, imaging studies, surgical findings, and microbiological evidence were categorized into lower respiratory infection, urinary tract infection, infective endocarditis, bacteremia with febrile neutropenia, uncomplicated skin and soft tissue infection and complicated skin and soft tissue infection (cSSTI), central nervous system infection, central catheter-associated bloodstream infection, and intra-abdominal infections (including biliary tract infection). cSSTI is defined as a heterogeneous package of disorders in healthy people with severe infection, patients with major comorbidities and relatively minor infection, patients with extensive cellulitis and systemic symptoms who can be managed with antibiotics alone to patients with necrotizing limb-threatening infection that requires life-saving surgery, and diabetic foot infections.\textsuperscript{23} Febrile neutropenia is defined as an oral temperature of \(>38.5^\circ\text{C}\) or 2 consecutive readings of \(>38.0^\circ\text{C}\) for 2 hours and an absolute neutrophil count of \(<0.5 \times 10^9/\text{L}\) (or expected to fall below \(0.5 \times 10^9/\text{L}\)). If no source was identified, the infection was categorized as primary bacteremia. In addition, the infection was classified as primary bacteremia if the blood culture was not consistent with any culture from the site of the suspected infectious focus, including sputum, urine, wound, deep tissue, cerebrospinal fluid, central catheter tip, bile, or ascites.

Treatment duration was defined as the period from the day of appropriate antimicrobial agent use to the end of the treatment. We also recorded patients’ treatment with appropriate antibiotics within 3 days or not, and also the time to appropriate antibiotics. Patients requiring surgical intervention or drainage and the duration between bacteremia occurrence and intervention were also recorded. Clinical outcomes were assessed using 30-day crude mortality.

2.5. Statistical analyses

All statistical analyses were performed using the Statistical Package for Social Sciences for Windows (version 18.0; SPSS Inc., Chicago, IL). Categorical variables were compared using the \(\chi^2\) test or Fisher exact test, as appropriate; continuous variables were compared using the Mann–Whitney \(U\) test. Variables with \(P \leq 0.05\) in the univariate analysis were included in a multiple logistic regression model for identifying risk factors for 30-day mortality. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. All tests were 2-tailed, and \(P < 0.05\) was considered significant.

3. Results

3.1. Patient enrollment and their clinical characteristics

A total of 482 VGS blood isolates were identified during 2014 to 2015. On the basis of our inclusion criteria, 170 (35.3\%) patients were excluded because they were aged < 18 years, or because of suspected contamination, duplicate data, or lost or incomplete medical records. Finally, 312 (64.7\%) patients with individual unduplicated VGS blood isolates were enrolled (Fig. 1).

The demographic and clinical characteristics of the patients are listed in Table 1. Of the 312 patients, 64.1\% were men with a mean age of 62.4 years. The duration between hospital admission and VGS bacteremia occurrence ranged from 0 to 215 days with a mean interval of 41.2 ± 14.9 days. In total, 71 (22.8\%), 65 (20.8\%), 40 (12.8\%), 25 (8.0\%), 37 (11.9\%), and 23 (7.4\%) patients had received a CVC placement, had received immunosuppressants, ever used a ventilator, had an ICU stay, had severe sepsis or septic shock, and had neutropenia, respectively. The mean Pittsburgh bacteremia score was 1.3 ± 2.7.

3.1.1. Microbiology, concomitant diseases, treatment, and outcome.

This study observed the most common VGS group to be constituted by the S. anginosus group with 121 (38.8\%) isolates, followed by the S. mitis group with 71 (22.8\%) isolates. Of the 71 isolates of S. mitis group identified by MALDI-TOF MS Biotyper system, we randomized to chose 17 isolates (24\%) and confirmed by 16S rRNA sequencing (supplement Table 1, http:// links.lww.com/MD692). The 2 examination results showed 100% consistency. The most common concomitant disease was solid-organ malignancy (37.2\%), followed by diabetes mellitus (32.1\%) and chronic kidney disease stage IV and above (30.8\%). The treatment duration varied from 0 to 113 days with a mean duration of 16.8 ± 13.2 days; nearly, all 307 (98.4\%) patients had received appropriate antibiotics within 3 days. The time to appropriate antibiotics was 0.13 ± 0.4 days. There were 73
Table 1: Clinical characteristics of 312 patients with unduplicated viridans group streptococcus monomicrobial bacteremia.

| Variables                              | Value |
|----------------------------------------|-------|
| Demographic parameters                 |       |
| Age, y                                 | 62.4 (16.2) |
| Male gender                            | 200 (64.1) |
| Clinical conditions                     |       |
| Time interval between admission and occurrence of bacteremia, d | 4.1 (14.9) |
| Central venous catheter use             | 71 (22.8) |
| Immunosuppressant use                   | 65 (20.8) |
| Patients’ severity                      |       |
| Pittsburgh bacteremia score             | 1.3 (2.7) |
| Ventilator use                         | 24 (0.8) |
| Total weight                            | 66 (21.2) |
| Intensive care unit stay                | 12 (0.4) |
| Intensive care unit stay                | 12 (0.4) |
| Severe sepsis or septic shock           | 37 (11.9) |
| Neutropenia                            | 23 (7.4) |

Microbiology:
- **Streptococcus anginosus group**: 121 (38.8)
- **S. anginosus**: 63 (20.2)
- **S. constellatus**: 50 (16)
- **S. intermedius**: 8 (2.6)
- **Streptococcus mitis group**:
  - **S. mitis**: 71 (22.8)
  - **S. oralis**: 19 (6.1)
  - **S. infantis**: 51 (16.3)
  - **S. sanguinis**: 1 (0.3)
- **Streptococcus bovis group**: 48 (15.4)
- **S. gallolyticus**: 46 (14.7)
- **S. lutensiae**: 2 (0.6)
- **Streptococcus sanguinis group**:
  - **S. sanguinis**: 35 (11.2)
  - **S. paraanginosus**: 11 (3.5)
  - **S. gordonii**: 14 (4.5)
- **Streptococcus salivarius group**:
  - **S. salivarius**: 34 (10.9)
  - **S. oralis**: 34 (10.9)
- **Streptococcus mutans group**:
  - **S. mutans**: 3 (1)
  - **S. infantis**: 3 (1)
- Concomitant diseases:
  - Solid organ malignancy: 116 (37.2)
  - Diabetes mellitus: 100 (32.1)
  - Severe renal impairment: 96 (30.8)
  - Liver cirrhosis: 77 (24.7)
  - Cerebral vascular accident: 48 (15.4)
  - Hematological malignancy: 15 (4.8)
  - Chronic pulmonary disease: 15 (4.8)

Treatment and outcome:
- Treatment duration: 16.8 (13.2)
- Appropriate antibiotics within 3 d: 307 (98.4)
- Time to appropriate antibiotics, d: 0.13 (0.4)
- Need for surgical intervention or drainage: 73 (23.4)
- Time to surgical intervention or drainage: 5 (7.9)
- 30-d crude mortality: 47 (15.1)

Source of bacteremia:
- Primary bacteremia: 61 (19.6)
- Intra-abdominal infection: 91 (29.2)
- Biliary tract infection: 51 (16.3)
- Intra-abdominal infection except biliary tract infection: 40 (12.8)
- Skin and soft tissue infection: 57 (18.3)
- Complicated skin and soft tissue infection: 36 (11.5)
- Infective endocarditis: 38 (12.2)
- Lower respiratory tract infection: 30 (9.6)
- Bacteremia with febrile neutropenia: 18 (5.8)
- Central catheter associated blood stream infection: 8 (2.6)
- Urinary tract infection: 5 (1.6)
- Central nervous system infection: 4 (1.3)

(continued)

Table 1 (continued):

| Variables                              | Value |
|----------------------------------------|-------|
| **Antibiogram (resistance)**           |       |
| Erythromycin                           | 111 (35.6) |
| Clindamycin                            | 79 (25.3) |
| Penicillin                             | 39 (12.5) |
| Ampicillin                              | 13 (4.2) |
| Ceftriaxone                             | 7 (2.2) |
| Glycopeptides                          | 0 (0) |
| Resistance to more than 1 kind of antibiotics | 104 (33.3) |

* Categorical data: number (%) of patients; continuous data are expressed as the mean (standard deviation).
† Streptococcus mitis group did not include S. pneumoniae and S. pseudopneumoniae.

(23.4%) patients in need for surgical intervention or drainage, and the duration between bacteremia occurrence and surgical intervention or drainage was 5 ± 7.9 days. Finally, 30-day crude mortality was 15.1%.

3.2. Infection sources of different VGS groups

Sixty-one (19.6%) patients had primary bacteremia, and the remaining 251 (80.4%) patients had identified sources of bacteremia (Table 1). The most common source of bacteremia was intra-abdominal infection (91/251, 36.34%), followed by skin and soft tissue infection (SSTI; 57/251, 22.7%). Figure 2 depicts the infectious sources of all VGS bacteremia and 6 main VGS groups.

Patients with *S. anginosus* group bacteremia had a higher frequency of SSTI (*P* < .001) and biliary tract infection (*P* = .051) and a lower frequency of infective endocarditis (*P* < .001) and bacteremia with febrile neutropenia (*P* < .001; Table 2). Patients with *S. mitis* group bacteremia had a higher frequency of infective endocarditis (*P* = .027) and bacteremia with febrile neutropenia (*P* < .001) and a lower frequency of biliary tract infection (*P* = .005). Patients with *S. sanguinis* group bacteremia were also more likely to have infective endocarditis (*P* = .009).

3.3. Antibiotic resistance of different VGS groups

Most patients showed antibiotic resistance to erythromycin (35.6%), followed by clindamycin (25.3%) and penicillin (12.5%; Table 1). One hundred four (33.3%) patients had resistance to more than 1 type of antibiotic. Regarding the antibiotic resistance profiles of different VGS groups, *S. anginosus* group had less resistance to ampicillin, erythromycin, clindamycin, and ceftriaxone (0.8%, 20.7%, 14.8%, and 0%; *P* = .019, < .001, .001, and .046, respectively) (Table 3). *S. bovis* group had higher resistance to erythromycin and clindamycin (54.2% and 50%, *P* = .003 and < .001, respectively) and less resistance to penicillin (0%, *P* = .004). Besides, *S. sanguinis* group had higher resistance to ampicillin (13.7%, *P* = .009) and *S. salivarius* group had higher resistance to penicillin (29.4%, *P* = .002).

3.4. Risk factors for 30-day mortality of patients with VGS bacteremia

Significant factors associated with 30-day mortality in the univariate analysis included underlying solid-organ malignancy, severe renal impairment, liver cirrhosis, a longer time interval.
Figure 2. The infection source of different species group of viridans group streptococcus. *Mitis group: except Streptococcus pneumoniae and S. pseudopneumoniae.

### Table 2
Relationship between different infection sources and different groups of viridans group streptococci.

| Group                      | S. anginosus group (n=121) | S. mitis group (n=71) | S. bovis group (n=48) | S. sanguinis group (n=35) | S. salivarius group (n=34) | S. mutans group (n=3) |
|----------------------------|-----------------------------|-----------------------|-----------------------|---------------------------|---------------------------|-----------------------|
| Skin and soft tissue infection (n=57) | 36 (29.8)                  | 8 (11.3)              | 6 (12.5)              | 3 (8.6)                   | 4 (11.8)                  | 0 (0)                 |
|   P                        | <.001                       | .082                  | .261                  | .162                      | .356                      | 1.000                 |
| Biliary tract infection (n=51) | 26 (21.5)                  | 4 (5.6)               | 10 (20.8)             | 5 (14.3)                  | 6 (17.6)                  | 0 (0)                 |
|   P                        | .051                        | .005                  | .361                  | 1.000                     | .807                      | 1.000                 |
| Infective endocarditis (n=38) | 4 (3.3)                    | 14 (19.7)             | 9 (18.8)              | 9 (25.7)                  | 1 (2.9)                   | 1 (33.3)              |
|   P                        | <.001                       | .027                  | .130                  | .009                      | .097                      | .324                  |
| Bacteremia with febrile neutropenia (n=18) | 0 (0)                      | 13 (18.3)             | 1 (2.1)               | 1 (2.9)                   | 3 (6.8)                   | 0 (0)                 |
|   P                        | .001                        | <.001                 | .327                  | .705                      | .428                      | 1.000                 |

Categorical data: number (%) of different groups of viridans group streptococcus patients.
*Mitis group did not include S. pneumoniae and S. pseudopneumoniae.

### Table 3
Susceptibility testing of different groups of viridans group streptococci.

| Group                       | S. anginosus group (n=121) | S. mitis group (n=71) | S. bovis group (n=48) | S. sanguinis group (n=35) | S. salivarius group (n=34) | S. mutans group (n=3) |
|-----------------------------|-----------------------------|-----------------------|-----------------------|---------------------------|---------------------------|-----------------------|
| Ampicillin resistance (n=13) | 1 (0.8)                    | 5 (7)                 | 0 (0)                 | 5 (14.3)                  | 2 (5.9)                   | 0 (0)                 |
|   P                         | .019                        | .181                  | .231                  | .009                      | .641                      | 1.000                 |
| Penicillin resistance (n=39) | 11 (9.1)                   | 11 (15.5)             | 0 (0)                 | 7 (20)                    | 10 (29.4)                 | 0 (0)                 |
|   P                         | .147                        | .386                  | .004                  | .154                      | .002                      | 1.000                 |
| Erythromycin resistance (n=111) | 25 (20.7)                | 29 (40.8)             | 26 (54.2)             | 15 (42.9)                 | 15 (44.1)                 | 0 (0)                 |
|   P                         | <.001                       | .291                  | .003                  | .184                      | .270                      | .555                  |
| Clindamycin resistance (n=79) | 18 (14.9)                  | 19 (26.8)             | 24 (50)               | 11 (31.4)                 | 7 (20.6)                  | 0 (0)                 |
|   P                         | .001                        | 7.51                  | <.001                 | .378                      | 5.01                      | .574                  |
| Ceftriaxone resistance (n=7) | 0 (0)                      | 3 (4.2)               | 1 (2.1)               | 2 (5.7)                   | 1 (2.9)                   | 0 (0)                 |
|   P                         | .046                        | .200                  | 1.000                 | .179                      | .771                      | 1.000                 |

Categorical data: number (%) of different groups of viridans group streptococcus patients.
*Mitis group did not include S. pneumoniae and S. pseudopneumoniae.
between admission and bacteremia occurrence, a higher Pittsburgh bacteremia score, more ICU stay, severe sepsis or septic shock, immunosuppressant use and neutropenia, and bacteremia source with lower respiratory tract infection. Infection source with SSTI, longer treatment duration, and more surgical intervention or drainage improved the outcome (Table 4). Different VGS groups and antibiogram and resistance profiles did not reveal a difference in outcomes. The factors associated with 30-day mortality in the univariate analysis were entered into the multivariate analysis, and the results showed that a longer ICU stay (adjusted OR, 6.002; 95% CI, 2.159–16.69; \(P=.001\)) and underlying solid organ malignancy (adjusted OR, 2.736; 95% CI, 1.09–6.871; \(P=.032\)) were independent risk factors for 30-day mortality. A longer treatment duration was an independent protective factor for 30-day mortality (adjusted OR, 0.917; 95% CI, 0.866–0.971; \(P=.003\); Table 4).

### Table 4

Univariate and multivariate analyses of risk factors for 30-day crude mortality of groups of viridans group streptococcus bacteremia.

| Variables                                      | Deceased\(^a\) n = 47 | Survived\(^b\) n = 265 | Univariate OR (95% CI), \(P\) | Multivariate OR (95% CI), \(P\) |
|------------------------------------------------|------------------------|-------------------------|-------------------------------|---------------------------------|
| Demographic parameters                         |                        |                         |                               |                                 |
| Age, y 64.4 (14.2)                              | 62 (16.5)              | .582                    |                               |                                 |
| Male gender 29 (61.7)                           | 171 (64.5)             | .710                    |                               |                                 |
| Concomitant diseases                            |                        |                         |                               |                                 |
| Solid organ malignancy 27 (57.4)                | 89 (33.6)              | .002                    | 2.736 (1.09–6.871), .032      |                                 |
| Diabetes mellitus 12 (25.5)                    | 88 (33.2)              | .209                    |                               |                                 |
| Severe renal impairment 23 (48.9)              | 73 (27.5)              | .003                    | 2.388 (0.99–5.758), .053      |                                 |
| Liver cirrhosis 17 (36.2)                      | 60 (22.6)              | .047                    | 2.082 (0.834–5.196), .082     |                                 |
| Cerebral vascular accident 9 (19.1)            | 39 (14.7)              | .436                    |                               |                                 |
| Hematological malignancy 4 (8.5)               | 11 (4.2)               | .256                    |                               |                                 |
| Chronic pulmonary disease 4 (8.5)              | 11 (4.2)               | .256                    |                               |                                 |
| Clinical conditions                             |                        |                         |                               |                                 |
| Time interval between admission and occurrence of bacteremia, d 10.7 (33.6) | 3 (7.6) | .014 | 1.031 (0.986–1.04), .349 |                                 |
| Immunosuppressant use 18 (38.3)                | 47 (17.7)              | .01                      | 2.161 (0.684–6.829), .189      |                                 |
| Patients’ severity                              |                        |                         |                               |                                 |
| Pittsburgh bacteremia score 3.9 (4.2)          | 0.8 (2)                | <.001                   | 1.113 (0.929–1.333), .247      |                                 |
| ICU stay 26 (65.3)                              | 40 (15.1)              | <.001                   | 6.002 (2.159–16.69), .001      |                                 |
| Severe sepsis or septic shock 18 (38.3)        | 19 (7.2)               | <.001                   | 2.238 (0.534–9.372), .27       |                                 |
| Neutropenia 7 (14.9)                           | 16 (6)                 | .032                    | 1.129 (0.248–5.142), .676      |                                 |
| Source of bacteremia                            |                        |                         |                               |                                 |
| Primary bacteremia 6 (12.8)                    | 55 (20.8)              | .203                    |                               |                                 |
| Intra-abdominal infection 15 (31.9)            | 76 (28.7)              | .653                    |                               |                                 |
| Skin and soft tissue infection 1 (2.1)         | 56 (21.1)              | .001                    | 0.273 (0.032–2.364), .238      |                                 |
| Lower respiratory tract infection 12 (25.5)    | 18 (6.8)               | <.001                   | 2.062 (0.699–6.08), .19        |                                 |
| Infective endocarditis 7 (14.9)                | 31 (11.7)              | .537                    |                               |                                 |
| Bacteremia with febrile neutropenia 4 (8.5)    | 14 (5.3)               | .328                    |                               |                                 |
| Central catheter associated blood stream infection 2 (4.3) | 6 (2.3) | .345 |                               |                                 |
| Central nervous system infection 0 (0)         | 4 (1.5)                | 1.000                   |                               |                                 |
| Urinary tract infection 0 (0)                  | 5 (1.9)                | 1.000                   |                               |                                 |
| Microbiology                                    |                        |                         |                               |                                 |
| *S. anginosus* group 15 (31.9)                  | 106 (40)               | .294                    |                               |                                 |
| *S. mitis* group 11 (23.4)                     | 60 (22.6)              | .908                    |                               |                                 |
| *S. bovis* group 11 (23.4)                     | 37 (14)                | .098                    |                               |                                 |
| *S. sanguinis* group 8 (17)                    | 27 (10.2)              | .171                    |                               |                                 |
| *S. salivarius* group 2 (4.3)                  | 32 (12.1)              | .133                    |                               |                                 |
| *S. mutans* group 0 (0)                        | 3 (1.1)                | 1.000                   |                               |                                 |
| Antibiogram (resistance)                       |                        |                         |                               |                                 |
| Erythromycin 19 (40.4)                         | 92 (34.7)              | .451                    |                               |                                 |
| Clindamycin 15 (31.9)                          | 64 (24.2)              | .259                    |                               |                                 |
| Penicillin 5 (10.6)                            | 34 (12.8)              | .675                    |                               |                                 |
| Ampicillin 2 (4.3)                             | 11 (4.2)               | 1.000                   |                               |                                 |
| Ceftriaxone 1 (2.1)                            | 6 (2.3)                | 1.000                   |                               |                                 |
| Resistance >1 class antibiotics 16 (34)        | 88 (33.2)              | .911                    |                               |                                 |
| Treatment                                      |                        |                         |                               |                                 |
| Treatment duration 11.1 (7.4)                  | 17.8 (13.8)            | .001                    | 0.917 (0.866–0.971), .003      |                                 |
| Appropriate antibiotics within 3 d 45 (95.7)    | 262 (98.9)             | .165                    |                               |                                 |
| Time to appropriate antibiotics, d 0.1 (0.5)   | 0.1 (0.4)              | .782                    |                               |                                 |
| Need for surgical intervention or drainage 5 (10.6) | 68 (25.7) | .025 | 0.405 (0.119–1.377), .148     |                                 |
| Time to surgical intervention or drainage 2 (2.7) | 5 (2.7) | .377 |                               |                                 |

\*All variables with \(P<.05\) in the univariate analysis were included in a multivariate regression model by using the backward stepwise method.

CI = confidence interval, ICU = intensive care unit, OR = odds ratio.

\* *Streptococcus mitis* group did not include *S. pneumoniae* and *S. pseudopneumoniae*.
4. Discussion

Viridans streptococci and the β-hemolytic streptococci constitute a diverse group of organisms with varying environmental niches and pathogenicity. In the previous era, VGS was usually only identified to the genus level due to the limitation of traditional biochemistry tests. Our hospital conducted MALDI-TOF MS for all bacteria identification since June 2013.[2] Although several previous studies had questioned about the ability of MALDI-TOF MS for identifying VGS into species level, especially misidentification S. mitis to S. pneumoniae, the accuracy for identification to the group level was generally acceptable.[15,16] The updated MALDI Biotyper database showed better performance, provided precise species-level information, and produced no misidentifications of the S. mitis species group strains, as S. pneumoniae with sensitivity and specificity was closed to 100%. Our identification of S. mitis group also showed high consistancy results between MALDI-TOF Biotyper and 16S rRNA sequencing without misidentification to S. pneumoniae. Indeed, using gene sequencing methods might well identify VGS to the species level but is not practical in the real-world settings and limits the ability of clinicians to readily recognize the clinical significance of these VGS. In this study, we did a comprehensive survey of different VGS groups and their clinical manifestations, infection sources, concomitant diseases, treatments, and outcomes in post-MALDI-TOF MS era.

VGS can cause various clinical diseases from infective endocarditis[11] to bacteremia[20] to infection related to malignancy.[15] In the preantibiotic era, VGS accounted for approximately 75% of cases of infective endocarditis. Currently, the relative frequency of VGS in association with infective endocarditis has decreased to as low as 20%.[10] In our study, the S. mitis group, S. bovis group, and S. sanguinis groups were responsible for 36.8%, 23.7%, and 23.7% of infective endocarditis, respectively, with a significantly higher ratio than that of other VGS groups. By contrast, the association of the S. anginosus group with infective endocarditis was weak. This finding is supportive of those previous studies.[17,18,31] For accurate diagnosis of infective endocarditis, the identification of VGS is necessary and helpful.

In the setting of a malignancy, bacteremia with VGS is more common in children than in adults, typically developing after chemotherapy or bone marrow transplantation at the time of profound neutropenia. In addition, the relationship between VGS and hematological malignancy or neutropenia was found in adult patients.[32] S. mitis was the causative organism in most such cases and responsible for severe complications, including shock and acute respiratory failure.[19,33] Although studies specifically evaluating these virulent streptococcal infections in adults are scant, the previously reported incidence ranged from 0% to 26% depending on the population analyzed.[19] In our study, we also found a significant correlation of S. mitis group infections and bacteremia with febrile neutropenia.

Earlier observations showed that a striking feature of the S. anginosus group was its members’ tendency to cause abscesses.[34] Claridge et al.[34] demonstrated that of 60 patients, 22 and 9 had soft tissue infection and intra-abdominal infection, respectively. In our study, the S. anginosus group more likely caused pyogenic infection, including intra-abdominal infection (31.4%) and SSTI (29.3%). Although VGS did not constitute the major pathogens of SSTI and intra-abdominal infection, these infections still play a crucial role in S. anginosus group bacteremia. Streptococcal bone and joint infections are less common than staphylococcal cases. A study reported that the percentages of S. anginosus and S. constellatus infection were 11% and 10%, respectively, in all 93 patients with Streptococcal bone and joint infections.[35] Despite Enterobacteriaceae being the major bacterial cause of intra-abdominal infection, abscess caused by the S. anginosus group with a high recurrence rate should still be noted.[36]

Although VGS are generally susceptible to most anti-Gram positive agents, resistance occurs against macrolides, tetracycline, and penicillin.[37] The developing penicillin resistance is an emergency in VGS.[38] Alcaide et al.[39] indicated that antimicrobial resistance to penicillin differed among these species: S. mitis, 41.5%; S. sanguinis, 41.7%; S. salivarius, 28.1%; and S. anginosus, 14% (P <.01). Szužik et al.[40] reported that the rates of resistance and reduced sensitivity of isolates for penicillin and ampicillin were 61.2% and 55.1%, respectively. The rate of resistance to penicillin and ampicillin was as high as 75% in the S. sanguinis group. Chun et al.[41] showed that the rates of resistance to penicillin, ampicillin, and ceftriaxone were 40%, 32.8%, and 11.2%, respectively. In our study, the S. anginosus group had a low resistance to ampicillin, ceftriaxone, erythromycin, and clindamycin. And S. bovis group had the higher resistance to erythromycin (45.2%) and clindamycin (50%), similar with the results of Streit et al.[42] However, a limitation of our study is that we used only the disk diffusion method for the susceptibility test, but not the broth microdilution method or E-test.

Limitation of our study was the lack of confirmative tests with 16S rRNA sequencing for all isolates to affirm the accuracy of the results of MALDI-TOF MS. However, the consistency was noted by randomly selected isolates with S. mitis group, which was previously known as the weak point of MALDI-TOF Biotyper system. Besides, our drug susceptibility testing does not use broth microdilution but disc diffusion test. However, this restriction faithfully represented the real-world situation. And the clinical physicians still could receive a lot of assistance of the VGS presentations by knowing their groups identification.

In conclusion, we conducted the largest comprehensive study during the recent years about the different VGS groups and their clinical manifestations, infection sources, concomitant diseases, susceptibility tests, treatments, and outcomes. Different VGS groups had variable underlying diseases, clinical behavior, and drug susceptibility. Therefore, identification of VGS by MALDI-TOF MS has important clinical impacts for physicians.

Author contributions

Conceptualization: Ting-Yi Su, Jang-Jih Lu.
Data curation: Ting-Yi Su, Tsui-Ping Liu, Jang-Jih Lu.
Formal analysis: Ting-Yi Su, Ching-Tai Huang, Tsui-Ping Liu, Jang-Jih Lu.
Investigation: Ting-Yi Su, Ming-Hsun Lee, Ching-Tai Huang, Jang-Jih Lu.
Methodology: Ting-Yi Su, Ming-Hsun Lee, Jang-Jih Lu.
Project administration: Ting-Yi Su, Jang-Jih Lu.
Resources: Ting-Yi Su, Tsui-Ping Liu, Jang-Jih Lu.
Software: Ting-Yi Su.
Supervision: Ting-Yi Su, Ching-Tai Huang, Jang-Jih Lu.
Validation: Ting-Yi Su, Tsui-Ping Liu, Jang-Jih Lu.
Visualization: Ting-Yi Su, Jang-Jih Lu.
Writing – original draft: Ting-Yi Su.
Writing – review & editing: Ting-Yi Su, Ming-Hsun Lee, Jang-Jih Lu.
References

[1] Gibbons RJ, vanHoute J. Selective bacterial adherence to oral epithelial surfaces and its role as an ecological determinant. Infect Immun 1971;3:367–73.

[2] Doern GD, Burnham CAD. It’s not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations. J Clin Microbiol 2010;48:3829–35.

[3] Bruckner DA, Colonna P. Nomenclature for aerobic and facultative bacteria. Clin Infect Dis 1997;25:1.

[4] Lopez RP, Sanchez CC, Marin M, et al. Value of matrix-assisted laser desorption ionization-time of flight for routine identification of viridans group streptococci causing bloodstream infections. Clin Microbiol Infect 2013;19:438–44.

[5] Karpános P, Harju I, Rantakokko-Jalava K, et al. Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of viridans group streptococci. Eur J Clin Microbiol Infect Dis 2014;33:779–88.

[6] Zhou M, Yang Q, Kudinha T, et al. Using matrix-assisted laser desorption ionization-time of flight MALDI-TOF mass spectrometry to detect 16S rRNA and gyrB gene sequences to practically identify clinical important Viridans group Streptococci (VGS). Front Microbiol 2016;7:328.

[7] Kawamura Y, Hou XG, Sultana F, et al. Determination of 16S rRNA sequences of Streptococcus mitis and Streptococcus gordonii and phylogenetic relationships among members of the genus Streptococcus. Int J Syst Bacteriol 1995;45:406–8.

[8] Poyart C, Quesne G, Coulon S, et al. Identification of streptococci to species level by sequencing the gene encoding the manganese-dependent superoxide dismutase. J Clin Microbiol 1998;36:41–7.

[9] Angeletti S, Dicuonzo G, Avola A, et al. Viridans group streptococci clinical isolates: MALDI-TOF mass spectrometry versus gene sequence-based identification. Eur J Clin Microbiol Infect Dis 2014;33:254–6.

[10] Facklam R. What happened to the streptococci: overview of taxonomic changes. Clin Microbiol Rev 2002;15:613–30.

[11] Ferren P, Gewirtz MH, Gerber MA, et al. Unique features of infective endocarditis in childhood. Pediatr Infect Dis 2002;21:91–43.

[12] Geggel RL. Conditions leading to pediatric cardiology consultation in a tertiary academic hospital. Pediatrics 2004;114:e409–17.

[13] Martin JM, Neches WH, Wald ER. Infective endocarditis: 35 years of experience at a children’s hospital. Clin Infect Dis 1997;24:669–75.

[14] Nielsen MJ, Claxton S, Pizer B, et al. Viridans group Streptococcal infections in children after chemotherapy or stem cell transplantation: a 10-year review from a tertiary pediatric hospital. Medicine (Baltimore) 2016;95:e2022.

[15] Hasun E, Whitehead S, Castell A, et al. Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility. Pediatr Infect Dis J 2005;24:563–6.

[16] Lewis V, Yanofsky R, Mitchell D, et al. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. Pediatr Infect Dis J 2014;33:126–9.

[17] Nilson B, Olaison L, Rasmussen M. Clinical presentation of infective endocarditis caused by different groups of non-beta haemolytic streptococci. Eur J Clin Microbiol Infect Dis 2016;35:215–8.

[18] Isaksen J, Rasmussen M, Nilson B, et al. Comparison of species identification of endocarditis associated viridans streptococci using rmpB genotyping and 2 MALDI-TOF systems. Diagn Microbiol Infect Dis 2015;81:240–5.

[19] Marron A, Carratala J, González-Barca E, et al. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000;31:1126–30.

[20] Dubois D, Segonds C, Marty N, et al. Identification of clinical Streptococcus pneumoniae isolates among other alpha and nonhemolytic streptococci by use of the Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry system. J Clin Microbiol 2013;51:1861–7.

[21] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 27th M100. Clinical and Laboratory Standards Institute: PA, USA; 2017.

[22] Chow JW, Fine MJ, Slaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1993;115:585–90.

[23] Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65:35–44.

[24] Ikryannikova LN, FilimonoVA AV, Malakhova MV, et al. Discrimination between Streptococcus pneumoniae and Streptococcus mitis based on sorting of their MALDI mass spectra. Clin Microbiol Infect 2013;19:1066–71.

[25] Marin M, Cercendao E, Sánchez-Carrillo C, et al. Accurate differentiation of Streptococcus pneumoniae from other species within the Streptococcus mitis group by peak analysis using MALDI-TOF MS. Front Microbiol 2017;8:698.

[26] Werno AM, Christner M, Anderson TP, et al. Differentiation of Streptococcus pneumoniae from nonpneumococcal Streptococci of the Streptococcus mitis group by matrix-assisted laser desorption ionization: time of flight mass spectrometry. J Clin Microbiol 2012;50:2863–7.

[27] Stinga CS, Eichrich K, Theil J, et al. Identification of viridans streptococci with matrix-assisted laser desorption &amp ionization time-of-flight mass spectrometry by an in-house method and a commercially available system. Ann Lab Med 2017;37:434–7.

[28] Harju I, Lange C, Kostrewza M, et al. Improved differentiation of Streptococcus pneumoniae and other S. mitis group Streptococci by MALDI biotyper using an improved MALDI biotyper database content and a novel result interpretation algorithm. J Clin Microbiol 2017;55:914–22.

[29] Elting LS, Bodey GP, Keefe B, H.Leptospirosis and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201–7.

[30] Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002;288:75–81.

[31] Naveen Kumar V, van derLinden M, Menon T, et al. Viridans and bovis group streptococci that cause infective endocarditis in two regions with contrasting epidemiology. Int J Med Microbiol 2014;304:262–8.

[32] Han XY, Kamana M, Rolston KVI. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 2010;48:3829–35.

[33] Shelburne SA, Saharabhojane P, Saldana M, et al. Streptococcus mitis strains causing severe clinical disease in cancer patients. Emerg Infect Dis 2014;20:762–71.

[34] Cladige JE, Attorri S, Musher DM, et al. Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus (“Streptococcus milleri group”) are of different clinical importance and are not equally associated with abscess. Clin Infect Dis 2001;32:1511–5.

[35] Seng P, Vernier M, Gay A, et al. Clinical features and outcome of bone and joint infections with streptococcal involvement: 5-year experience of interregional reference centres in the south of France. New Microbes New Infect 2016;12:8–17.

[36] Bellko J, Goldmann D, a , et al. Clinically significant infections with organisms of the Streptococcus milleri group. Pediatr Infect Dis J 2002;21:715–23.

[37] Mendes RE, Hogan PA, Streit JM, et al. Zyvox ( Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12): J Antimicrob Chemother 2014;69:1382–8.

[38] Westling K, Julander I, Ljungman P, et al. Viridans group streptococci in blood culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin resistance genes. Int J Antimicrob Agents 2006;28:292–6.

[39] Alcaide F, Liñares J, Pallares R, et al. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995;39:2243–7.

[40] Szuik S, Kaykatepe B, Çetin M. Antimicrobial susceptibility against penicillin, ampicillin and vancomycin of viridans group streptococci in oral microbiota of patients at risk of infective endocarditis. Infec Med 2016;24:190–3.

[41] Chun S, Huh HJ, Lee NY. Species-specific difference in antimicrobial susceptibility among viridans group streptococci. Ann Lab Med 2015;35:205–11.

[42] Streit JM, Steenbergen JN, Thorne GM, et al. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. J Antimicrob Chemother 2005;55:574–8.